FacebookTwitterGoogle+RedditEmail

Ghostwriting Your Meds

Under Obama’s plan—assuming there is a plan—the pharmaceutical industry in all likelyhood escapes price regulation. For its part,the industry promises $30 million to support the elderly in Medicare to buy brand name drugs.

Controversy often surrounds the release of brand name drugs,that is, are they—as the federal laws long have stipulated—safe and efficacious. We often rely on independent medical journals to provide important information and analysis to make the case for their use. We trust the editors of these journals and the experts who write the articles for knowledge and sound judgement. And it’s not just the general public who trusts them.Doctors use this information as an important factor in deciding whether or not to prescribe a drug.

So it comes as something of a shock to many people when they discover that these articles are sometimes not written by the people who sign them.Instead,they are the work of a team of ghostwriters employed by individual companies pushing the drugs Dr. Adriane Fugh Berman, a doctor at Georgetown University and a colleague of mine in a publically funded project called Pharmedout.org,is making public a series of internal documents ghostwritten for Wyeth-Ayers in 1996 in an effort to promote Premarin and Prempro, two controversial estrogen replacement therapy drugs. Fugh-Berman heself has been an expert witness in a suit against Wyeth-Ayerst.

The documents, being released in batches, speak for themselves. Here is one of them ,introduced by Fugh-Berman in a blog for PloS Medicine, a medical publication. The New York Times has also written about the documents and published another set.

Our story to date: Wyeth-Ayerst (“the client”) paid DesignWrite, a medical education and communication company (MEC), to write and submit papers to medical journals as part of promotional efforts for Premarin- (conjugated equine estrogens) – and Prempro, which adds medroxyprogeterone acetate to CEE.

The first step is to choose the target journal best suited to the manuscript’s content. …We will then analyze the data and write the manuscript, recruit a suitable well-recognized expert to lend his/her name as author of the document, and secure his/her approval of its content. After the client has reviewed and released the manuscript for submission, DesignWrite will see it through the necessary production stages — creating camera-ready figures and tables and the text according to the journal guidelines — and submit the package (manuscript, art, cover letter, and any required forms and checklists) to the appropriate journal editor… Any revisions requested by the journal will be handled by DesignWrite in conjunction with the client and the author. Should the journal reject the manuscript, DesignWrite will restyle it for submission to another journal within 10 working days.” (1)

From receipt of the internal summary report for a given study, a time frame of one to two months is estimated for manuscript development. The time frame between submission of the draft and the client approval is subject to the client’s internal review. Subsequent revisions, based on client, author, or reviewer comments, are typically addressed in two to three weeks. A period of six to sixteen months is projected for actual publication once the manuscript has been accepted by the journal. The latter time frame is solely a function of individual journal policies.

The following is a typical work flow plan for developing a manuscript for submission to a peer-reviewed journal:

Client provides data report………. TBD
DesignWrite prepares outline………. 2 weeks
Client internal review………. 2 weeks
DesignWrite prepares first draft………. 4-8 weeks
Client internal review………. 2 weeks
DesignWrite addresses consolidated
client comments (second draft)………. 2-3 weeks
Second draft reviewed by selected author………. 2 weeks
DesignWrite incorporates author comments
(third draft)………. 2 weeks
DesignWrite assists in journal submission………. 2 weeks
Journal provides peer-reviewer comments………. TBD
DesignWrite addresses comments; resubmits………. 2 weeks
Journal acceptance and publication………. TBD

Manuscripts are submitted to peer-reviewed journals directed at the target audiences. Where appropriate, articles dealing with pharmacologic aspects of the drugs will be placed in journals with a pharmacology orientation. These articles could combine updates on study results as well as information comparing the product with other selected therapeutic agents. In addition, they could address trends in treatment and topical issues in patient management.

Selected data derived from individual studies could be published together as supplements to target journals within a particular therapeutic specialty. Should the client wish to pursue this publication option, the following guidelines are applicable. A turnaround time of six months is generally adhered to for producing the supplement. This includes all editorial components, including interactions with invited authors, and the target journal. Timing of the publication is ultimately predicated by the individual journal’s supplement schedule. Journal supplements could be published before product launch and be targeted to specific audiences.

Scientific Poster Presentations

At selected medical meetings, lead investigators are able to present the results of their in vitro, preclinical, or clinical studies in an academic atmosphere that many meeting attendees consider desirable. DesignWrite is quite experienced and successful in working with these investigators to ensure that their results are presented in a clear, professional, and impactful manner. Such presentations often represent merely abstracts of studies while others are more thorough. In either event, DesignWrite feels strongly that such poster presentations represent a significant manner of presenting scientific information to target audiences, particularly in preparation for the launch of a product and even postlaunch.

Budget

Preclinical manuscript………. $10,000
Clinical manuscript…………… $16,000
Review article………………….. $20,000
Poster presentation…………… $6,000
Journal supplement………….. $175,000 (2)

References:

1.DESIGN151927. The explanation is in an e-mail dated March 24, 1999 from Rosie Lynch of DesignWrite to Alice Conti of Wyeth Marketing.

2. DW065764. Medical Education and Communications Plan for the Premarin Product Line. Proposal for Jeff Solomon, Senior Product Manager, ERT/HRT,Wyeth-Ayerst Laboratories. Submitted by DesignWrite,Inc. August 12, 1996 (3) (See DW 065773, DW 065774 DW 065775 within this document).

Competing interest statement: Adriane Fugh-Berman has been a paid expert witness on behalf of plaintiffs in the multidistrict litigation against hormone manufacturers referred to in this blog.

JAMES RIDGEWAY can be reached at The Unsilent Generation.

 

 

 

 

 

 

 

 

 

 

More articles by:

James Ridgeway is an investigative reporter in Washington, DC. He co-edits Solitary Watch.

June 25, 2018
Daniel Falcone
A Reporter’s Reporter: a Conversation With Seymour Hersh
Gerald Sussman
America’s Cold War “Tugboat”
Jonathan Cook
The Defiance that Launched Gaza’s Flaming Kites Cannot be Extinguished
P. Sainath
A Long March of the Dispossessed to Delhi 
Sheldon Richman
What Does Trump Have Against Children?
Lance Olsen
Caught in a Trap of Our Own Making: Climate Change, Blame, and Denial
Seth Sandronsky
A Safe Black Space
Kary Love
Crying Children and Due Process of Law
Gary Leupp
Why It Just Makes Sense for the U.S. to Withdraw from the UNHRC
John Laforge
Kings Bay Plowshares Action Names the Trident with Blood
Mel Gurtov
After Singapore, Is Iran the Next US Target?
Kent D. Shifferd
A Different Perspective on Peace
Uri Avnery
Two Souls
Laura Flanders
National Suicide Point?
Ludwig Watzal
The Death of Felicia Langer
Weekend Edition
June 22, 2018
Friday - Sunday
Karl Grossman
Star Wars Redux: Trump’s Space Force
Andrew Levine
Strange Bedfellows
Jeffrey St. Clair
Intolerable Opinions in an Intolerant Time
Paul Street
None of Us are Free, One of Us is Chained
Edward Curtin
Slow Suicide and the Abandonment of the World
Celina Stien-della Croce
The ‘Soft Coup’ and the Attack on the Brazilian People 
James Bovard
Pro-War Media Deserve Slamming, Not Sainthood
Louisa Willcox
My Friend Margot Kidder: Sharing a Love of Dogs, the Wild, and Speaking Truth to Power
David Rosen
Trump’s War on Sex
Mir Alikhan
Trump, North Korea, and the Death of IR Theory
Christopher Jones
Neoliberalism, Pipelines, and Canadian Political Economy
Barbara Nimri Aziz
Why is Tariq Ramadan Imprisoned?
Robert Fantina
MAGA, Trump Style
Linn Washington Jr.
Justice System Abuses Mothers with No Apologies
Martha Rosenberg
Questions About a Popular Antibiotic Class
Ida Audeh
A Watershed Moment in Palestinian History: Interview with Jamal Juma’
Edward Hunt
The Afghan War is Killing More People Than Ever
Geoff Dutton
Electrocuting Oral Tradition
Don Fitz
When Cuban Polyclinics Were Born
Ramzy Baroud
End the Wars to Halt the Refugee Crisis
Ralph Nader
The Unsurpassed Power trip by an Insuperable Control Freak
Lara Merling
The Pain of Puerto Ricans is a Profit Source for Creditors
James Jordan
Struggle and Defiance at Colombia’s Feast of Pestilence
Tamara Pearson
Indifference to a Hellish World
Kathy Kelly
Hungering for Nuclear Disarmament
Jessicah Pierre
Celebrating the End of Slavery, With One Big Asterisk
Rohullah Naderi
The Ever-Shrinking Space for Hazara Ethnic Group
Binoy Kampmark
Leaving the UN Human Rights Council
Nomi Prins 
How Trump’s Trade Wars Could Lead to a Great Depression
Robert Fisk
Can Former Lebanese MP Mustafa Alloush Turn Even the Coldest of Middle Eastern Sceptics into an Optimist?
FacebookTwitterGoogle+RedditEmail